Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
97.80    -16.80 (-14.66%)
Bid:
99.90
Ask:
100.80
Spread: 0.90 (0.901%)
Market Cap: £160.34m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Q4 and FY trading update

20 Jan 2017 07:00

RNS Number : 6689U
Synthomer PLC
20 January 2017
 

Official Entity Name: SYNTHOMER PLC

LEI: 213800EHT3TI1KPQQJ56

 

20 January, 2017

 

Synthomer plc

 

Q4 and FY trading update

 

Synthomer plc ('Synthomer' or 'the Group') today issues a trading update for the year ended 31 December 2016.

 

Europe and North America

The positive trends experienced in our Europe and North America business during the first three quarters of the year continued through Q4 leading to an overall performance ahead of our original expectations. We saw better than expected results across all business segments and further benefits from the ongoing focus on efficiency, new product initiatives, a strengthened procurement function and investment in business development activities.

 

Asia and Rest of World

Asia and Rest of World also performed modestly ahead of our expectations in Q4 with the competitive dynamics in our Asian Nitrile business continuing to evolve following the introduction of additional industry capacity in the second half of the year. Full year 2016 volumes and margins for this business are now likely to be sequentially ahead of FY 2015.

 

Hexion PAC

The integration and trading performance of Hexion PAC continues to progress in line with our expectations. The underlying annual EBITDA and expected synergies remain unchanged from the guidance given to the market in March 2016.

 

Full Year 2016

Due to the combination of a stronger trading performance in Europe and a slower evolution of the Asian Nitrile dynamics during Q4, we now expect 2016 performance on an underlying constant currency basis to be ahead of the top end of current market expectations.(1)

 

In addition, the Group will also benefit from the translation effect related to the ongoing weakness of sterling. Average YTD FX rates were €1.22 and $1.35, and are expected to provide a translational benefit of approximately £12m for the full year.

 

In reported currency, taking into account both these factors, the Board now anticipates that FY 2016 PBT will be approximately £120m.

 

2017 outlook

Looking forward to 2017, we still expect to see resilient trading in Europe although the raw material and macroeconomic environments remain volatile. We also expect our Asian Nitrile business to be further impacted by the introduction of the additional industry capacity in 2016. This will be partially offset by a full year of Hexion PAC included in the Group's results.

 

The Group will provide further detail on the outlook for 2017 with its 2016 Full Year results on 6 March 2017.

 

1. FY 2016 Consensus: Constant Currency Profit before Tax between £92.0m - £103.9m with consensus at £98.3m (Compiled by Teneo Blue Rubicon)

 

-ENDS-

 

Enquiries:

Stephen Bennett, Chief Financial Officer +44 1279 775 250

Charles Armitstead, Teneo Blue Rubicon +44 203 603 5220

 

The Company will hold a conference call for investors and analysts at 0900 BST today.

Please dial +44 (0) 808 237 0030 entering conference ID: 61421287# to gain access to the call.

 

The Company considers this announcement to contain inside information

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTFMGMMRLZGNZM
Date   Source Headline
22nd Jun 20261:31 pmRNSResults of AGM
22nd Jun 20267:00 amRNSAGM trading statement
19th Jun 20267:00 amRNSDivestment of Acrylate Monomers
1st Jun 20262:42 pmRNSHolding(s) in Company
29th May 20263:57 pmRNSTotal Voting Rights
22nd May 20265:21 pmRNSNotice of AGM
8th May 20264:33 pmRNSAdmission to Trading
7th May 20261:51 pmRNSApplication for Admission to Trading
5th May 20264:25 pmRNSHolding(s) in Company
30th Apr 20264:40 pmRNSAnnual Financial Report
30th Apr 20263:17 pmRNSDirector/PDMR Shareholding
30th Apr 202611:25 amRNSDirector/PDMR Shareholding
30th Apr 20267:01 amRNSChange of Chief Financial Officer
30th Apr 20267:00 amRNSFinal Results
19th Mar 20267:00 amRNSTrading and refinancing update
11th Feb 20261:46 pmRNSStatement re potential refinancing
29th Jan 20267:00 amRNSTrading Statement - Winter 2026
27th Jan 20264:51 pmRNSHolding(s) in Company
26th Jan 20264:23 pmRNSHolding(s) in Company
18th Dec 20257:00 amRNSReceivables purchasing arrangement
12th Dec 20259:30 amRNSDirectorate change
12th Nov 20257:00 amRNSDirector/PDMR Shareholding
5th Nov 20251:28 pmRNSHolding(s) in Company
23rd Oct 20257:00 amRNSTrading statement - Autumn 2025
14th Oct 20257:00 amRNSAppointment of joint corporate broker
4th Sep 20255:17 pmRNSHolding(s) in Company
11th Aug 20258:00 amRNSDirector/PDMR Shareholding
6th Aug 20259:45 amRNSDirector/PDMR Shareholding
5th Aug 202511:57 amRNSDirector/PDMR Shareholding
5th Aug 202511:00 amRNSDirectorate Change
5th Aug 20257:00 amRNSInterim results
4th Jul 20257:01 amRNSDirector/PDMR Shareholding
1st Jul 20257:00 amRNSCovenant update
30th Jun 20257:00 amRNSDirectorate Changes
27th Jun 20254:21 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSDivestment of William Blythe completed
6th May 20257:00 amRNSDivestment of William Blythe
1st May 20254:18 pmRNSResults of AGM
1st May 20257:00 amRNSTrading Statement - Spring 2025
15th Apr 20253:00 pmRNSHolding(s) in Company
28th Mar 20257:30 amRNSDirector/PDMR Shareholding
27th Mar 20257:30 amRNSDirector/PDMR Shareholding
25th Mar 20254:23 pmRNSAnnual Report and Notice of AGM
25th Mar 202511:43 amRNSDirector/PDMR Shareholding
25th Mar 202511:41 amRNSDirector/PDMR Shareholding
24th Mar 20257:30 amRNSHolding(s) in Company
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
17th Mar 20259:00 amRNSDirector/PDMR Shareholding
11th Mar 20257:00 amRNSFinal Results
6th Mar 20258:32 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.